Dronabinol and Epidiolex (Cannabidiol) for Uncontrolled Residual Symptoms of Buprenorphine Initiation (Demure Trial)
About This Grant
ABSTRACT Opioid use disorder (OUD) and opioid overdose deaths remain shockingly high, fueled by fentanyl. Buprenorphine is an effective treatment for OUD, but successful treatment of people who use fentanyl has been hampered by protracted opioid withdrawal symptoms which can last even 6 months. There is evidence that Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) each could improve protracted opioid withdrawal symptoms and OUD outcomes in POUD who use fentanyl. However, using them separately has downsides—THC alone can cause intolerable side effects, and using CBD alone does not address as many symptoms as when it is used together with dronabinol. Dronabinol (synthetic THC) and Epidiolex (CBD) are two FDA approved cannabinoids that are pharmaceutical grade and are ideal products to test the effectiveness and safety of THC and CBD as an adjunct to buprenorphine in improving retention in OUD treatment and reducing opioid use. We will enroll 40 POUD early in treatment with buprenorphine with continued opioid use or cravings in a 12-week pilot randomized trial of dronabinol + Epidiolex (vs. placebo). Our primary outcome variable is retention in OUD treatment and secondary outcomes are opioid use, opioid withdrawal symptoms, pain severity and adverse events (panic, anxiety, and poor cognition). Finally, we will explore the mechanism by which cannabinoids improve OUD outcomes in POUD. Findings from this pilot study will inform the design, implementation, and power calculations for a future R01 which will examine the efficacy of dronabinol + Epidiolex as an adjunct to buprenorphine and rigorously examine potential mechanisms of opioid withdrawal symptoms, including cravings and pain.
Grant Summary
Dronabinol and Epidiolex (Cannabidiol) for Uncontrolled Residual Symptoms of Buprenorphine Initiation (Demure Trial) is a NIDA - National Institute on Drug Abuse grant providing up to $252K for university, nonprofit, healthcare org. Applications are due 2029-03-31 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $252K
2029-03-31
- 1Confirm your organization is eligible for Dronabinol and Epidiolex (Cannabidiol) for Uncontrolled Residual Symptoms of Buprenorphine Initiation (Demure Trial) from NIDA - National Institute on Drug Abuse, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIDA - National Institute on Drug Abuse before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIDA - National Institute on Drug Abuse's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Dronabinol and Epidiolex (Cannabidiol) for Uncontrolled Residual Symptoms of Buprenorphine Initiation (Demure Trial): Frequently Asked Questions
Who is eligible for the Dronabinol and Epidiolex (Cannabidiol) for Uncontrolled Residual Symptoms of Buprenorphine Initiation (Demure Trial)?
Dronabinol and Epidiolex (Cannabidiol) for Uncontrolled Residual Symptoms of Buprenorphine Initiation (Demure Trial) is offered by NIDA - National Institute on Drug Abuse and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Dronabinol and Epidiolex (Cannabidiol) for Uncontrolled Residual Symptoms of Buprenorphine Initiation (Demure Trial) provide?
Dronabinol and Epidiolex (Cannabidiol) for Uncontrolled Residual Symptoms of Buprenorphine Initiation (Demure Trial) provides up to $252K per award from NIDA - National Institute on Drug Abuse. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Dronabinol and Epidiolex (Cannabidiol) for Uncontrolled Residual Symptoms of Buprenorphine Initiation (Demure Trial) deadline?
Applications for Dronabinol and Epidiolex (Cannabidiol) for Uncontrolled Residual Symptoms of Buprenorphine Initiation (Demure Trial) are due 2029-03-31 (open). Because deadlines can change, verify the date with the funder, NIDA - National Institute on Drug Abuse, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Dronabinol and Epidiolex (Cannabidiol) for Uncontrolled Residual Symptoms of Buprenorphine Initiation (Demure Trial)?
To apply for Dronabinol and Epidiolex (Cannabidiol) for Uncontrolled Residual Symptoms of Buprenorphine Initiation (Demure Trial), confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIDA - National Institute on Drug Abuse.